Metotrexat Accord

Methotrexate, the active ingredient in Metotrexat Accord, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intrathecal administration. It is used to treat autoimmune disorders and certain malignancies in adult patients.

GNH USA supplies Metotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics where required, facilitating consistent product availability across global markets with dedicated technical support for end‑users.

Methotrexate is employed across several disease categories, primarily targeting rapidly dividing cells and immune‑mediated pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin lesion formation and severity. - Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control through cytotoxic activity. - Breast cancer: used as adjuvant therapy to limit tumor growth. - Ectopic pregnancy: terminates trophoblastic tissue by disrupting DNA synthesis.

Methotrexate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Oral mucositis (mouth sores) - Elevated liver enzymes

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Bone marrow suppression leading to pancytopenia - Acute renal failure or nephrotoxicity

When using methotrexate, careful monitoring and patient counseling are essential to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: conduct periodic liver enzyme tests to identify hepatotoxicity. - Evaluate renal function: check serum creatinine and clearance before and during therapy. - Avoid use in pregnancy: methotrexate is contraindicated due to teratogenic risk; ensure effective contraception. - Counsel on infection risk: advise patients to report signs of infection promptly. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Methotrexate interacts with several medicines; some combinations must be avoided while others require close monitoring.

Major Interactions (Avoid): - NSAIDs: increase methotrexate toxicity by reducing renal clearance. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Live vaccines: heightened risk of infection due to immunosuppression. - Azathioprine or other immunosuppressants: may cause excessive immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect gastrointestinal absorption. - Phenytoin and other enzyme inducers: can lower methotrexate plasma levels. - Alcohol: potentiates hepatic toxicity. - Folate supplements: may reduce efficacy; adjust dosing under medical guidance.